Here are the Form 4 insider transactions from Alzamend Neuro, Inc. (ALZN) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ALZN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALZN filings page.
Alzamend Neuro, Inc. (ALZN) director Milton C. Ault III reported selling 2,000 shares of common stock in open-market transactions on August 26, 2026 at a volume weighted average price of $1.5581 per share, reducing his directly held shares to 0. He continues to report indirect ownership of Alzamend Neuro common stock, including shares held through Ault Lending, LLC, Ault Life Sciences, Inc., and Ault Life Sciences Fund, LLC. Ault calculated a short-swing profit on matchable transactions that he intends to disgorge to Alzamend Neuro under Section 16(b) of the Exchange Act.
Alzamend Neuro, Inc. (ALZN) had an amended insider report from director Milton C. Ault III correcting previously omitted purchases on April 14, 2026. An entity associated with him, Ault Lending, LLC, bought 108,388 shares of common stock at about $1.0047 per share, held indirectly, bringing that entity’s holdings to 116,648 shares. Ault also directly purchased 2,000 shares at a volume weighted average price of $1.0338 per share, with trading that day occurring between $1.00 and $1.05 per share. He is also reported to have indirect holdings of 11,068 shares through Ault Life Sciences, Inc. and 61 shares through Ault Life Sciences Fund, LLC.
Alzamend Neuro, Inc. (ALZN) director Milton C. Ault III reported additional purchases of common stock on April 14, 2026 in an amended Form 4. An affiliated entity, Ault Lending, LLC, bought 108,388 shares at $1.0047 per share, and Ault personally bought 2,000 shares with a volume weighted average price of $1.0338, in open market transactions. Following these transactions, reported holdings include 116,648 indirect shares via Ault Lending, 11,068 indirect shares via Ault Life Sciences, Inc., 61 indirect shares via Ault Life Sciences Fund, LLC, and 2,000 direct shares.
Alzamend Neuro, Inc. (symbol: ALZN) is the issuer of record for a Form 4/A filing submitted to the SEC.
Hyperscale Data, Inc., a director-by-deputization of Alzamend Neuro, Inc., reported that its indirectly controlled subsidiary Ault Lending, LLC received a grant of 7,500 shares of Alzamend’s Series D Convertible Preferred Stock on July 31, 2026 at a reported price of $1,000.00 per share, resulting in indirect holdings of 7,500 preferred shares.
Each Series D share has a stated value of $1,050.00 and is convertible into common stock at a variable Conversion Price. As of August 4, 2026, the Conversion Price was $1.016 per share, so each preferred share was then convertible into approximately 1,033.5 common shares. The filing also lists several existing common stock purchase warrants held indirectly through Ault Lending.
Alzamend Neuro director Milton C. Ault III, through Ault Lending, LLC, acquired 7,500 shares of Series D Convertible Preferred Stock on July 31, 2026 as a grant. Each share has a stated value of $1,050.00 and is convertible into Common Stock at a variable Conversion Price; as of August 4, 2026, each was convertible into approximately 1,033.5 Common shares. The filing also lists indirect holdings of several Common Stock purchase warrants and direct stock options for 100,000 shares at a $2.33 exercise price expiring in 2035.
Alzamend Neuro, Inc. director Milton C. Ault III, through affiliated entities, reported an indirect open-market purchase of 108,388 shares of common stock at $1.0047 per share on April 14, 2026, executed by Ault Lending, LLC.
After this trade, Ault Lending, LLC held 116,648 common shares. Separate indirect holdings disclosed include 11,068 shares held by Ault Life Sciences, Inc. and 61 shares held by Ault Life Sciences Fund, LLC, with Mr. Ault having voting and investment power over these entities’ positions.